ZEB2 and breast cancer: Gregory et al. first indicated that miR-205 and the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) suppressed the EMT by targeting zinc finger E-box binding homeobox 1 (ZEB1) and Smad-interacting protein 1 (SIP1, also known as ZEB2) in breast cancer [185].